A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age17-85
SponsorLepu Biopharma Co., Ltd.
About this trial
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.
Eligibility criteria
Qualifiers
Understand and provide written informed consent and comply with the requirements set forth in the protocol.
age ≥ 18 years, ≤ 75 years.
Expected survival ≥ 3 months.
For patients with stage I and II disease, tumor tissue samples for GPC3 and P53 testing must be provided.
Disqualifiers
Moderate and above thoracoabdominal pelvic fluid and pericardial effusion with clinical symptoms.
History of liver failure and hepatic encephalopathy.
Portal vein tumor thrombus involving both the main portal vein and left and right branches, or involving both the main portal vein and mesenteric vein needs to be excluded. The tumor involves the vena cava, or has formed a vena cava tumor thrombus.
Residual toxicity due to previous anti-tumor therapy or clinically significant laboratory abnormalities higher than grade 1 (CTCAEv5.0).
Trial design
Treatments tested in this trial
- MRG006A
Treatment groups
343 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov